Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide

Respiratory Medicine

Volumn 92, Issue SUPPL. B, 1998, Pages 2-6

  Boobis, A R ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; GLUCOCORTICOID RECEPTOR;

ASTHMA; CHEMICAL STRUCTURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUBILITY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LIVER METABOLISM; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECEPTOR AFFINITY; SHORT SURVEY; STRUCTURE ACTIVITY RELATION;

EID: 0031659645     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90434-6     Document Type: Article

References (29)

1. Pavord I, Knox A. Pharmacokinetic optimisation of inhaled steroid therapy in asthma. Clin Pharmacokinet 1993; 25: 126-135.
2. Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984; 28: 485-518.
3. Rohdewald P, Von Eiff M, Wurthwein G. Activation of beclomethasone dipropionate in bronchial secretion, and receptor affinities and solubility of inhalationally administered glucocorticoids. Atternw-Lungenkrkh 1990; 16: 79-84.
4. Ryrfeldt Å, Andersson P, Edsbäcker S, Tönnesson, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63 (Suppl. 122): 89-95.
5. Ryrfeldt Å, Edsbäcker S, Pauwels R. Kinetics of epimeric glucocorticoid budesonide. Clin Pharmacol Ther 1984; 35: 525-530.
6. Tunek A, Sjodin K, Hallstrom G. Reversible formation of fatty acid esters of budesonide, an antiasthmatic glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997; 25: 1311-1317.
7. Lin YZ, Shieh KH. Metered dose inhaler and nebuliser in acute asthma. Arch Dis Child 1995; 72: 214-218.
8. Parkin PC, Sanders NR, Diamond SA et al. Randomised trial spacer vs. nebuliser for acute asthma. Arch Dis Child 1995; 72: 239-240.
9. Chou KJ, Cunningham SJ, Crain EF. Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. Arch Pediatr Adolesc Med 1995; 149: 201-205.
10. Wurthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone 17 monopropionate. Biopharm Drug Dispos 1990; 11: 381-394.
11. Martine LE, Harrison C, Tanner RJN. Metabolism of beclomethasone dipropionate by animals and man. Postgrad Med J 1975; 51 (Suppl. 4): 11-20.
12. Falcoz C, Kirby SM, Smith J, Olsson P, Ventresca GP. Pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate. Eur Respir J 1996; 9 (Suppl. 23): 126S (abstract P1062).
13. Harrison L, Soria I, Machacek J et al. Beclomethasone pharmacokinetics in asthmatics given CFC and CFC-free inhalers. Eur Respir J 1996; 9 (Suppl. 23): 256S (abstract P1625).
14. Harrison LI, Purrington A, Leach C, Machacek J, Vanden Burgt J, Vogel J. Beneficial effects with reduced particle size of CFC-free ultrafine aerosol steroid on lung deposition, absorption, efficacy and safety. Am J Respir Crit Care Med 1997; 155: A666.
15. Ellul-Micallaf R, Hansson E, Johansson SA. Budesonide; a new corticosteroid aerosol in bronchial asthma. Eur J Respir Dis 1980; 61: 167-173.
16. Pedersen S, Steffesnsen G, Ekman I, Tönnesson M, Borgå O. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol 1987; 31: 579-582.
17. van den Bosch JMM, Westermann CJJ, Aumann J et al. Concentration in lung tissue of inhaled budesonide. Rovaniemi Semin. 15-17 June 1989.
18. Astra Draco, data on file.
19. Andersson P, Ryrfeldt Å. Biotranformation of the topical glucocorticoids budesonide and beclomethasone (17,21) dipropionate in human liver and lung homogenate. J Pharm Pharmacol 1984; 36: 763-765.
20. Jenner WN, Kirkham DJ. Immunoassay of beclomethasone (17,21) dipropionate and metabolites. In: Reid E, Robinson JD, Wilson ID, eds. Bioanalysis of Drugs and Metabolites. New York: Plenum, 1988, pp 77-86.
21. Edsbäcker S, Andersson P, Lindberg C et al. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab Dispos 1987; 15: 403-411.
22. Edsbäcker S, Jönsson S, Lindberg C et al. Metabolic pathways of the topical glucocorticoid budesonide in man. Drug Metab Dispos 1983; 11: 590-596.
23. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication. Clinical implications of differences in effectiveness. Clin Immunother 1996; 4: 273-299.
24. Short R. Corticosteroid doses for asthma halved with CFC-free inhalers. Inpharma 1996; 1059: 13.
25. Barley C. Inhalation devices and aerosol therapy. On Contin Pract 1989; 16: 30-39.
26. Bai TR. Glucocorticosteroid treatment of asthma. Can Fam Phys 1995; 41: 1921-1927.
27. Pedersen S. Delivery options for inhaled therapy in children over the age of 6 years. J Aerosol Med Depos Clear Eff Lung 1997 10 (Suppl. 1): S41-S44.
28. Griffiths K. Breathing easy. Pharm Pract 1997; 9: 40-44.
29. Bisgaard H. Delivery options for inhaled therapy in children under the age of 6 years. J Aerosol Med Depos Clear Eff Lung 1997 10 (Suppl. 1): S41-S44.